Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-3007 + Pegcetacoplan in Geographic Atrophy
NCT07215390Phase 2Recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of APL-3007 (3 arms), sponsored by Apellis Pharmaceuticals. Primary endpoint: Change from baseline in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
APL-3007
Beyond the preview
Go deeper on NCT07215390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215390.